Background: The use of autologous peripheral blood progenitor cells (PBPC) expedites hematologic recovery and reduces the costs of transplantation in comparison with autologous bone marrow; however, its efficacy in patients with Hodgkin's disease has been questioned. We evaluated the results of autologous PBPC transplantation in a population of unselected and uniformly treated patients with primary refractory or relapsed Hodgkin's disease.
Introduction
Approximately one-third of patients with advanced Hodgkin's disease will fail initial treatment, either due to inability to attain a complete response to chemotherapy, or due to relapse, usually within three years post therapy [1, 2] . Salvage of those patients with conventional chemotherapy has been associated with poor results: in the two largest series the long-term overall survival was 0%-8% for patients with primary refractory disease, and ll%-28% and 24%-54% for patients with early relapsed (within a year post therapy) and late relapsed (more than a year post therapy) Hodgkin's disease, respectively [1, 2] . A prospective randomized comparison between high-dose and conventional-dose BEAM (BCNU, etoposide, ara-C, melphalan) chemotherapy in patients with chemotherapy refractory or early relapsed Hodgkin's disease proved the superiority of high-dose chemotherapy (HDC) in terms of eventfree survival (53% versus 10% at three years), which led to early termination of the trial [3] . Multiple other single-arm series of patients with primary refractory or relapsed Hodgkin's disease treated with HDC with autologous hematopoietic progenitor-cell transplantation have reported favorable results in comparison to conventional chemotherapy in all patient subgroups, including patients with long initial remissions, however, patient follow-up is not as long as in the conventional chemotherapy series [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Moreover, difficulties in the interpretation of the results of the HDC series arise from the heterogeneity of conditioning regimens and progenitor-cell sources, and selection bias.
In recent years, the use of peripheral blood as the source of autologous hematopoietic progenitor cells, advances in supportive care, and the routine use of hematopoietic growth factors have significantly reduced transplant-associated morbidity and mortality, which further strengthens the appeal of HDC. However, the optimal graft source for patients with Hodgkin's disease has been questioned after a report by the European Group for Blood and Marrow Transplantation (EBMT) in which patients with Hodgkin's disease treated with autologous peripheral blood progenitor cells (PBPC) demonstrated worse survival than those who received autologous bone marrow [17] . We recently reported low treatment-related mortality and the feasibility of outpatient treatment in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease undergoing high-dose BEAM chemotherapy followed by autologous PBPC transplantation [18] . We now report the outcome of patients with primary refractory or relapsed Hodgkin's disease treated with high-dose BEAM followed by autologous PBPC transplantation at Yale University.
Patients and methods

Study population
It has been our policy since June 1994 to offer HDC with BEAM followed by PBPC infusion to all patients with primary refractory or relapsed Hodgkin's disease with adequate organ function regardless of chemoresponsiveness, or other disease-related parameter. In order to evaluate the magnitude of patient selection in our institute, we reviewed all cases with Hodgkin's disease registered in the Yale Tumor Registry in the last 10 years. We found that 52 adult patients (16 years or older) were diagnosed with relapsed or primary refractory Hodgkin's disease following conventional chemotherapy between June 1994 and February 1999. Forty patients underwent HDC with BEAM followed by autologous PBPC transplantation (between September 1994 and June 1999), on a study protocol approved by the hospital's Human Investigation Committee, and are the subjects of this report. Of the 12 remaining patients, 7 were treated with HDC: 2 received CBV (cyclophosphamide, BCNU, VP-16) followed by autologous bone marrow transplantation at Yale, and 5 were offered HDC when seen in consultation but elected to be treated at other centers, usually due to proximity to their residence (all received autologous PBPC transplantation). The median age of these 7 patients was 30 years (range 17-38); 5 were chemosensitive and 2 had untested disease, 2 had stage III or IV disease at relapse/progression Five patients were not transplanted for the following reasons: 1) patient refusal, 2) no insurance coverage due to immigration status, 3) no therapy given due to an active systemic fungal infection in a 75-year-old patient, 4) not referred for transplantation due to advanced age (69 years), and 5) transplantation was not recommended by Pediatric Oncology for a 16-year-old boy with a 4-year disease-free interval who relapsed in one nodal area and was responsive to salvage conventional chemotherapy.
Patient characteristics
Forty patients with primary refractory (n = 7) or relapsed (n = 33) Hodgkin's disease after conventional chemotherapy underwent highdose BEAM chemotherapy followed by autologous PBPC transplantation (Tables 1-3 ). All patients received HDC at Yale-New Haven hospital, except for one patient who underwent HDC and PBPC infusion at a Yale-affiliated hospital. Chemotherapy regimens at original diagnosis included ABVD (« = 22) or ABVD-based (n = 5) in 67% of patients. Two of the patients with relapsed disease had a history of an additional relapse treated with radiation therapy alone. Of the patients transplanted on first relapse approximately half (13 out of 27) relapsed at an interval of less than a year following completion of their primary chemotherapy, whereas all patients transplanted on second relapse had an initial remission of more than one year, but their second remission interval was short (8 months or less in 4 out of 6 patients). Progression of disease was proved by biopsy or unequivocal radiographic findings. Pathology was reviewed at Yale Department of Pathology. 
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Salvage/cytoreductive and mobilizing conventional chemotherapy
Most of the patients (34 of 40) received salvage/cytoreductive conventional chemotherapy (median of 2 cycles, range 1-7) prior to receiving a mobilizing regimen ( Table 2 ). Salvage/cytoreductive chemotherapy served for tumor debulking, but was not administered with the intent of achieving a complete response or until best response. The mobilizing regimen consisted of cyclophosphamide and etoposide in most of the cases (n = 24). Other mobilizing regimens included dexamethasone, ara-C, cisplatin (DHAP) (ti = 6), and single-agent cyclophosphamide (n = 6). Five patients received more than one mobilizing regimens due to suboptimal PBPC collection after the first mobilization.
At the time of transplantation 52% (21 of 40) of patients had responded to salvage/cytoreductive chemotherapy and/or mobilizing regimen. 30% patients were refractory, and 17% were classified as untested disease (one with primary refractory and six with relapsed disease), either because they proceeded directly to mobilization and transplant and/or complete restaging studies were not available ( Table  3) . Two of the patients classified as having refractory disease responded initially to chemotherapy but at the time of transplantation had a rising lactate dehydrogenase (LDH). Pre-transplant evaluation included pulmonary function tests and a Multigated Angioscintigraphy (MUGA) scan to assess ejection fraction. (67) 6 (15) 5 (12) 12 (30) 16 (40) 12 10 (25) 1 (2) 12 (30) 4 (10) 3 (7) 2 (5) 5 (12) 3 (7) 6 (15) Post primary chemotherapy and post transplantation a Since diagnosis, excluding mobilizing regimen.
21 (52) 12 (30) 7 (17) 5 (12) 35 (87) 24 (60) 16 (40) 12 (30) 2(5) b From diagnosis of relapse/progression until the day of transplantation. Because of rounding, percentages may not: total 100. a Second remission interval for patients on second relapse. Abbreviations 1 DHAP -dexamethasone, ara-C, cisplatin; EPOCHetoposide, prednisone, vincristine, cyclophosphamide, adriamycin; ICE -ifosfamide, carboplatin, etoposide. Because of rounding, percentages may not total 100.
Conditioning regimen and infusion of hematopoietic progenitor cells
All patients received high-dose BEAM chemotherapy administered as follows: BCNU 300 mg/m 2 on day -6, etoposide 200 mg/m 2 twice daily on days -5 to -3 , ara-C 100 mg/m 2 twice daily on days -5 to -2, and melphalan 140 mg/m 2 on day -1 , followed by autologous PBPC infusion on day 0. For overweight patients the dose calculation was based on ideal weight plus 30%. One patient with early relapse underwent tandem transplantation with HDC with high-dose ICE followed five weeks later by high-dose BEAM. One patient who had suboptimal stem-cell collection (2 x 10 6 CD34+ cells per kg) underwent bone marrow harvesting and infusion of bone marrow in addition to PBPC. A median number of 6.17 x 10 6 CD34+ cells/kg were infused. In four cases the progenitor cells were infused in two consecutive days in order to avoid possible dimethylsulfoxide (DMSO) toxicity. Patients with bone marrow involvement had a relatively low number of CD34+ cells infused (all received less than 11 x 10 6 per kg).
Supportive care
All patients received high-dose G-CSF (10 mcg/kg) and prophylactic antibiotics, I e., ciprofloxacin, fluconazole, and acyclovir (for patients with positive herpes serology) post transplantation starting on day 0, as previously described [18] . As a result of the tolerability of the regimen, we shifted our patient care to the outpatient setting in 1996.
Since then, 24 of 28 patients (86%) have been treated as outpatients. Of 24 patients receiving HDC as outpatients, 7 (29%) were never admitted, whereas 17 patients required hospitahzation, usually for neutropenic fever or failure to thrive, for a median of 5 days. Outpatient HDC administration was not feasible in four cases due to problems with medical insurance coverage or inability to commute daily from home/hotel to hospital, or personal reasons. The hospital stay for patients receiving HDC as inpatients, ranged from 15-30 days, with a median of 19 days.
Post-transplant radiotherapy
Radiation therapy was routinely administered post transplantation to 1-2 sites of previous bulky disease not previously irradiated. Fourteen patients (35%) received post transplant radiation therapy that was started within one month of transplantation. Of these patients, two had previously received radiation therapy to other areas of disease. The delivered dose was usually equal or less than 3,000 cGy, and the radiation field included the mediastinum in 86% (12 of 14) of cases.
Definition of terms and endpoints, and statistical methods
Primary refractory disease was defined as inability to achieve a complete response (CR) at the completion of first-line chemotherapy. Partial response (PR) was defined as a 50% or more reduction in the tumor dimensions, without the development of new lesions. Patients with a PR as defined above but with a negative gallium scan at the completion of primary chemotherapy were considered to be in a CR. Relapsed disease was defined as recurrence after an initial CR. Chemosensitive disease to prior conventional chemotherapy was de-fined as a PR or CR to therapy, whereas chemorefractory disease was defined as stable or progressive disease. In addition, patients with clinical evidence of progression of disease at the time of transplantation (such as a rising LDH) were also considered to have chemoresistant disease. Overall survival (OS) was calculated from the time of transplantation to the time of death or last follow-up. Progressionfree survival (PFS) was calculated from the time of transplantation to the time of disease progression, last follow-up, or death without disease progression. Survival curves were generated using the Kaplan-Meier method, and compared using the log-rank test. Clinically significant variables with a /"-value of 0.05 or less were included in multivanate analysis using a Cox-regression model with backward stepwise selection.
Hazard ratios were derived with 95% confidence intervals. Statistical analysis was performed using the Statistical Package for Social Sciences for Windows, release 6.1 (SPSS Inc., Chicago, Illinois, USA).
Results
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Response to high-dose BEAM and survival
A total of 12 patients (30%) failed HDC: 3 never attained a CR, and 9 relapsed after achieving a post transplant CR, all within the first 12 months post transplant, at a median period of 5 months. Of the 37 patients (92%) in CR post transplantation, 14 had been in CR prior to transplantation, while 23 achieved a CR from a pre-transplant PR (n -7), no response (« = 9), or untested disease (n = 7). Of the three patients who failed to enter CR, two patients died within three months due to progressive disease, and the other patient died of treatment-related toxicity in the first two weeks post transplantation. Imaging studies prior to the death of the latter patient had shown progression of disease and autopsy findings confirmed the presence of active Hodgkin's disease. A total of 8 patients (20%) have died, 1 due to acute transplant-related complications, as mentioned above, 1 due to sudden death 12 months post transplantation, and 6 due to progression of disease 2-24 months post transplantation (median of 6.5 months). The PFS at 3 years was 69%, and the OS at 3 years was 77% (Figure 1) , with a median follow-up of surviving patients of 28 months (range 3-59 months).
Toxicity
Acute non-hematologic toxicities included diarrhea, mucositis, and nausea/vomiting (Table 4) . One treatment-related death occurred due to electrolyte abnormalities secondary to profound diarrhea (acute mortality rate of 2.5%). Total parenteral nutrition (TPN) was administered to nine patients (22%), for a median number of six days. Neutropenic fever developed in 27 patients (67%), lasting for a period of 1-8 days, with a median of 2 days. Symptomatic pneumonitis developed in six patients (15%), all of whom had a previous history of mantle/mediastinal irradiation, five post-and one prior to transplantation. In the latter case, pulmonary symptoms were likely due to progression of disease in the lung. In all other cases prompt initiation of steroids resulted in improvement in symptomatology. Eight paTime (months) Figure 1 Kaplan-Meier analysis of (a) progression-free survival (PFS) and (b) overall survival. With the exception of mortality rate, percentages were rounded.
tients had documented gram-positive bacteremia, but no patient developed gram-negative bacteremia or systemic fungal infection. The median number of post transplant days to an absolute neutrophil count of more than 500/ul and a platelet count of more than 20,000/ul (without transfusion support) was 9 and 10 days, respectively. A median number of 4 units of packed red blood cells (range 0-8) and a median of 18 units of platelets (range 4-54) were transfused within the first 2 months post transplantation. One patient was diagnosed with idiopathic thrombocytopenic purpura post transplantation. Mild prolonged pancytopenias developed in three patients, however, no cases of myelodysplastic syndrome were seen. One patient developed a Hurtle-cell thyroid cancer that was most likely present prior to transplantation as evident by previous thyroid ultrasound examinations. In another patient the histologic diagnosis of both Hodgkin's disease and non-Hodgkin's lymphoma were made at the time of progression of disease post transplantation. Finally, two patients developed iatrogenic hypothyroidism.
Prognostic parameters
The following variables were found to be associated with a poor PFS in univariate analysis (P < 0.05), using the log-rank test (Table 5 ): higher number of infused CD34+ PBPC (as a continuous variable as well as when using a cut-off value of 11 x 10 6 per kg), refractoriness to conventional chemotherapy, advanced Ann Arbor stage at relapse/progression (IIB-IV versus I-IIA), bone marrow involvement at relapse/progression, and primary refractory or very early relapsed disease (within 2 months) versus relapses >2 months. For relapsed patients (« = 33) the remission interval was not predictive of poor PFS.
In multivariate analysis, using a stepwise Cox regression model, chemorefractory disease (hazard ratio 15; P -0.0003), and advanced stage at relapse/progression, IIB-IV versus I-IIA (hazard ratio 14; P -0.003) were independently associated with poor PFS, whereas a higher number of infused CD34+ PBPC infused (> 11 x 10 6 per kg) was of borderline significance (P = 0.05; hazard ratio 4) ( Table 6 ). Results of Cox regression analysis, especially when differences of borderline significance are encountered, should be interpreted with caution due to the relatively small number of treatment failures in this study.
The following variables were associated with a poor OS in univariate analysis, using the log-rank test (P 0 .05): chemorefractory disease, advanced stage at relapse/progression (IIB-IV versus I-IIA), bone marrow involvement at relapse/progression, and older age. All five patients with elevated LDH at the time of transplantation died of disease progression.
Discussion
Autologous PBPC transplantation has been shown to expedite hematologic recovery and reduce hospital stays and costs of therapy compared to the use of autologous bone marrow [19, 20] . The current study as well as our previous report [18] demonstrate the low morbidity and mortality with high-dose BEAM with PBPC support and the feasibility of treatment in the outpatient setting. More importantly, the present study shows that highdose BEAM with PBPC infusion was efficacious in an For all comparisons. Abbreviation: NS -not statistically significant. unselected single-institution population of patients with primary refractory or relapsed Hodgkin's disease, achieving an actuarial PFS of 69% and OS of 77%, with a median follow-up of 28 months. In order to evaluate the possible effect of patient selection in our study we analyzed our data in the context of an institution-based tumor registry data review. Of all patients with primary refractory or relapsed Hodgkin's disease post conventional chemotherapy seen in our institute during the same period of time as the patients on study, only three were not offered or referred for HDC: two elderly patients (older than 69 years), one of whom had a systemic fungal infection, and a pediatric age patient (16 years old) who was thought to be in a good prognosis group, having a late chemosensitive relapse. However, we encountered no patient with pre-transplant limiting organ dysfunction.
In the first large series on the use of PBPC in Hodgkin's disease, Kessinger et al. treated 56 patients with relapsed Hodgkin's disease who had a hypocellular bone marrow or bone marrow involvement by tumor with CBV followed by PBPC [21] . They reported an eventfree survival (EFS) of 37% at three years for all patients, and 27% for the subset of patients with bone marrow tumor involvement. Horning et al. treated 119 patients with relapsed or primary refractory Hodgkin's disease with HDC with CBV or CCNU/VP-16/cyclophosphamide or a Total Body Irradiation-based regimen, followed by PBPC with or without bone marrow [9] . PBPC was initially utilized for patients with a history of prior pelvic irradiation, bone or bone marrow disease. They reported an actuarial 4-year OS of 52% and PFS of 62%, with a median follow-up of 40 months. Multiple other transplant series have included patients with Hodgkin's patients treated primarily with bone marrow transplantation. Chopra et al. reported an actuarial PFS of 50% and an OS of 55% at 5 years in 155 patients with primary refractory (30% of patients) or relapsed Hodgkin's disease undergoing high-dose BEAM chemotherapy followed by autologous bone marrow transplantation [10] . More recently, Lumley et al. using a similar conditioning regimen followed by bone marrow transplantation in 35 of 42 patients, demonstrated an EFS of 74%, with a median follow-up of 33 months [6] . Other single institution series using other conditioning regimens, such as CBV [12] , VP-16/melphalan [16] or BEAC [8] , reported PFS or EFS in the range of 25%-39%, with a median follow-up of 30-77 months. The selection of conditioning regimen does not appear to determine the outcome of transplantation [9, 13, 22] .
Concerns on the efficacy of the use of PBPC for the treatment of patients with Hodgkin's disease were raised by the results of a matched-control analysis of the EBMT data [17] . This analysis included a total of 128 patients with Hodgkin's disease for each group (bone marrow only versus PBPC only), including patients in first remission. The majority of patients received BEAM or CBV. The PFS was 52% versus 38% at 4 years, and the OS was 65% versus 53% at 4 years, favoring the bone marrow group, with a median follow-up of 27 months for the bone marrow group versus 19 months for the PBPC group. Treatment-related mortality was higher in the bone marrow group, but did not reach statistical significance (acute mortality 10% versus 5%) [17] . The validity and possible etiology of these findings is unclear. Bierman et al. reported that a small number of patients receiving PBPC in their study did worse compared to patients receiving bone marrow, but the PBPC patients also had poorer performance status and had failed more prior chemotherapy regimens [12] . Brice et al. found no difference between Hodgkin's disease patients treated at first relapse with autologous PBPC or bone marrow transplantation [13] . More studies on patients treated with PBPC and longer patient follow-up are needed to draw definitive conclusions regarding the long-term efficacy of PBPC transplantation.
Most studies, including the present report, have identified response to pre-transplant conventional chemotherapy or disease status at transplantation as strong predictors of outcome [8-10, 13, 16] . We found that chemorefractory patients had an actuarial PFS of only 22% compared to 89% for all other patients, and that patients with Ann Arbor stage IIB-IV at relapse/progression had a PFS of 46% versus 86% for patients with stage I-IIA. Similar to our findings, Brice et al. reported that advanced stage at relapse was an important prognostic factor [13] , and Horning et al. found that stage IV lung or bone marrow involvement, systemic symptoms at presentation for transplantation, and more than minimal residual disease before HDC were independent predictors of poor outcome [9] . In our study, all five patients with an elevated LDH just prior to receiving HDC died of progressive disease. Based on these observations, we conclude that patients with refractory disease, especially with evidence of progression at the time of transplantation, perform poorly with autologous PBPC transplantation, and should be considered for alternative treatment strategies, such as allogeneic transplantation.
The percentage of patients who enter CR post HDC was high in our study (92%), which is comparable to the study of Brice et al. (93%) [13] , but higher than the previously reported CR rates of 57% by Bierman et al. [12] and 75% by Crump et al. [16] , which may account for the favorable outcome of our patients. On the other hand, these differences may be related to variability in the definition of response between studies, such as the incorporation of gallium scan findings in defining CR in our study.
Previous large series of patients with primary refractory Hodgkin's disease reported PFS at 3-5 years in the range of 32%-42% [5, 7, 15] , whereas studies of patients with relapsed disease have demonstrated a somewhat longer PFS between 40%-64% [4, 11, 13, 14] . When patients with very early relapses (within two months post therapy completion) and patients with primary refractory disease were examined together in our study, they had worse PFS compared to patients with later relapses, in univariate analysis. However, this was not of independent significance in multivariate analysis. It is possible that ultimate chemoresposiveness is a more important determinant of survival than induction failure, i.e., patients who fail primary chemotherapy but respond to a salvage regimen may have a favorable prognosis.
An intriguing observation of our study was that a high number of infused PBPC O i l x 10 6 CD34+ cells per kg) was associated with a poor PFS. However, this was of borderline significance in multivariate analysis. If a correlation between infused PBPC number and relapse is confirmed, this could potentialy be due to the co-mobilization of tumor cells and hematopoietic progenitor cells, particularly in patients with active disease. The phenomenon of co-mobilizing tumor and hematopoietic progenitor cells has been observed in patients with solid tumors, especially in women with advancedstage breast cancer [23] , but also in patients with nonHodgkin's lymphoma [24] . Caballero et al. reported an association between the number of mononuclear cells infused and poor disease-free survival (DFS) in patients with non-Hodgkin's lymphoma treated with BEAM and PBPC or bone marrow transplantation [25] . Sharp et al. demonstrated that patients with non-Hodgkin's lymphoma receiving tumor contaminated products have a poor DFS [26] . While similar data are lacking in Hodgkin's disease, the presence of circulating Reed-Sternberg cells has been confirmed [27] . If contaminating tumor cells can be shown to give rise to recurrence rather than simply reflecting overwhelming and poorly responsive disease, it would suggest that a more vigorous treatment prior to PBPC collection, purging of the graft, or possibly the use of an allogeneic donor may improve outcome. Our findings caution against the infusion of an excessive number of CD34+ cells, however, the association between the number of infused CD34+ cells and outcome post autologous PBPC transplantation needs to be investigated in future studies.
